| DC44784 |
MC-AAA-NHCH2OCH2COO-7-aminomethyl-10-methyl-11-fluoro camptothecin |
MC-AAA-NHCH2OCH2COO-7-aminomethyl-10-methyl-11-fluoro camptothecin (compound 21a), a camptothecin payload, can be conjugated to a monoclonal antibody (mAb) for the synthesis of camptothecin antibody-drug conjugate (ADC). |
|
| DC44785 |
7-MAD-MDCPT |
7-MAD-MDCPT, a Camptothecin analog, is a toxin payload in antibody drug conjugates (ADCs). |
|
| DC44786 |
MC-AAA-NHCH2OCH2COOH |
MC-AAA-NHCH2OCH2COOH (compound 20) is a cleavable ADC linker that is used for making antibody-drug conjugate (ADC). |
|
| DC44787 |
MP-PEG4-VK(Boc)G-OSu |
MP-PEG4-VK(Boc)G-OSu is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). |
|
| DC44788 |
MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT |
MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT is a Camptothecin-linker compound extracted from patent WO2019195665A1, example 4-1. MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT is a drug-linker conjugate for antibody-drug conjugate (ADC). |
|
| DC45373 |
Bis-sulfone-PEG3-Azide |
Bis-sulfone-PEG3-Azide is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). |
|
| DC45523 |
Seco-DUBA hydrochloride |
Seco-DUBA hydrochloride is a toxin for ADC drug SYD985. |
|
| DC45695 |
Thailanstatin A
Featured
|
Thailanstatin A is an ultra-potent inhibitor of eukaryotic RNA splicing (IC50=650 nM). Thailanstatin A exerts effects via non-covalent binding to the SF3b subunit of the U2 snRNA subcomplex of the spliceosome and shows low-nM to sub-nM IC50s against multiple cancer cell lines. Thailanstatin A, a payload for ADCs, is conjugated to the lysines on trastuzumab yielding “linker-less” ADC. |
|
| DC45852 |
Lys-Nε-SPDB-DM4 |
Lys-Nε-SPDB-DM4 is a drug-linker conjugate composed of a potent a tubulin inhibitor DM4 and a linker Lys-Nε-SPDB to make antibody drug conjugate (ADC). |
|
| DC45920 |
MCC |
MCC is non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs), such as MCC-DM1. |
|
| DC45931 |
6-Oxohexanoic acid |
6-Oxohexanoic acid is a non-cleavable modified MMAF-C5-COOH linker and can be used in the synthesis of modified MMAF-C5-COOH, a drug-linker conjugate for ADC. |
|
| DC46006 |
Modified MMAF-C5-COOH |
Modified MMAF-C5-COOH is a drug-linker conjugate for ADC. |
|
| DC46041 |
Biotin-PEG4-SS-azide |
Biotin-PEG4-SS-azide is a cleavable, biotin-labeled, ADC linker used in the synthesis of antibody-drug conjugates (ADCs). |
|
| DC46087 |
MCC-DM1 |
MCC-DM1 is a drug-Linker Conjugates for ADC such ad Anti-CD22-MCC-DM1. |
|
| DC46088 |
Ozogamicin |
Ozogamicin is a drug-linker conjugates for ADC. Ozogamicin can used in the synthesis of gemtuzumab ozogamicin and inotuzumab ozogamicin. |
|
| DC46131 |
Acid-C3-SSPy
Featured
|
Acid-C3-SSPy is a cleavable DBA-DM4 linker used in the synthesis of DBA-DM4, a drug-linker conjugate for ADC.
|
|
| DC57041 |
N-Me-L-Ala-maytansinol
Featured
|
N-Me-L-Ala-maytansinol is a maytansine derivative. .N-Me-L-Ala-maytansinol can be used for synthesis of antibody-drug conjugate (ADC). |
|
| DC60106 |
MC-Ala-Ala-Asn(Trt)-PAB
Featured
|
MC-Ala-Ala-Asn(Trt)-PAB, is a hetero bifunctional cross-linker, useful in antibody drug conjugation (ADC). MC-Ala-Ala-Asn(Trt)-PAB is a fissionable linker which is specifically activated in a tumor microenvironment. XQN70430 was reported in patent WO 2016026458. |
|
| DC46199 |
DBCO-PEG4-Ahx-DM1
Featured
|
DBCO-PEG4-Ahx-DM1 is a drug-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody drug conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. |
|
| DC46201 |
MC-VC-PABC-SP 141 |
MC-VC-PABC-SP 141 is a drug-linker conjugate for ADC with potent antitumor activity by using SP 141 (a potent MDM2 inhibitor), linked via the cleavable ADC linker MC-VC-PABC. |
|
| DC46202 |
N3-PEG4-DYKDDDD-Doxorubicin |
N3-PEG4-DYKDDDD-Doxorubicin is a drug-linker conjugate for ADC with potent antitumor activity by using the cytotoxic anthracycline antibiotic, Doxorubicin, linked via the cleavable linker N3-PEG4-DYKDDDD. |
|
| DC46203 |
N3-PEG4-YPYDVPDYA-Doxorubicin |
N3-PEG4-YPYDVPDYA-Doxorubicin is a drug-linker conjugate for ADC with potent antitumor activity by using the cytotoxic anthracycline antibiotic, Doxorubicin, linked via the cleavable linker N3-PEG4-YPYDVPDYA. |
|
| DC46204 |
N3-PEG8-Phe-Lys-PABC-Gefitinib |
N3-PEG8-Phe-Lys-PABC-Gefitinib is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-tumor agent, Gefitinib (orally active EGFR tyrosine kinase inhibitor), linked via the cleavable linker N3-PEG8-Phe-Lys-PABC. |
|
| DC46211 |
FCHFHS-ST7612AA1 |
FCHFHS-ST7612AA1 is a part of antibody drug conjugates (ADCs) charged with HDAC inhibitor by a linker, shows antitumor activity. |
|
| DC46212 |
MAC-VC-PABC-ST7612AA1 |
MAC-VC-PABC-ST7612AA1 is a part of antibody drug conjugates (ADCs) charged with HDAC inhibitor by a linker, shows antitumor activity. |
|
| DC46213 |
OSu-PEG4-VC-PAB-Duocarmycin SA |
SA is a drug-linker conjugate for ADC with potent antitumor activity by using Duocarmycin SA (a potent DNA alkylation activator), linked via the cleavable ADC linker OSu-PEG4-VC-PAB. |
|
| DC46214 |
Sulfo-SPDB-DGN462 |
Sulfo-SPDB-DGN462 is a drug-linker conjugate for ADC. Sulfo-SPDB-DGN462 consists a toxin DGN462 conjugated to the cleavable Sulfo-SPDB linker. DGN462, a potent DNA-alkylating agent, shows anti-tumor activity, such as acute myeloid leukemia (AML).
|
|
| DC46215 |
Tubulysin IM-1 |
Tubulysin IM-1 is an ADC Cytotoxin and tubulin binder used as anti-microtubule toxins. |
|
| DC46238 |
MC-Val-Cit-PAB-dimethylDNA31 |
MC-Val-Cit-PAB-dimethylDNA31 is a drug-linker conjugate for ADC with potent antitumor activity by using dimethylDNA31, linked via the ADC linker MC-Val-Cit-PAB. DimethylDNA31 has effective bactericidal activity against persisters and stationary-phase S. aureus. |
|
| DC46251 |
Azide-PEG4-VC-PAB-Doxorubicin |
Azide-PEG4-VC-PAB-Doxorubicin is a drug-linker conjugate composed of a cytotoxic anthracycline antibiotic Doxorubicin and a linker Azide-PEG4-VC-PAB to make antibody drug conjugate (ADC). |
|
